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The synthesis of RNA molecules carrying acridine or quindoline molecules at 
their 3’-termini and 5’-termini is reported. These conjugates are fully characterized by 
MLADI-TOF mass spectrometry. Modified siRNA duplexes carrying acridine or 
quindoline residues were evaluated in the inhibition of the tumor necrosis factor. The 
conjugates showed similar inhibitory properties than unmodified RNA duplexes in 
HeLa cells transfected with oligofectamine. The fluorescent properties of acridine 
derivatives allow the direct observation of the cytoplasmatic distribution of modified 
siRNA inside the cells. 
 
Introduction. Chemically modified oligonucleotides have a tremendous 
potential as therapeutics. Antisense oligonucleotides were used against a wide range of 
targets and some chemically modified oligonucleotides have entered in the clinic. 
However, RNA interference (RNAi) has energized the field and the successful use of 
short interfering RNA (siRNA) for gene silencing has focused most of the attention. 
The opportunities of siRNA in therapeutics are reduced due to poor cellular uptake [1], 
degradation by nucleases [2] and side effects such as stimulation of the immune 
response [3]. Modified siRNA have solved partially some of these obstacles [4]. 
Conjugation of oligonucleotides with molecules that provide novel properties to the 
conjugate have been extensively used [5]. Small drug molecules, aptamers, lipids, 
peptides, carbohydrates or polymers are conjugated to siRNA to improve 
pharmacokinetic behaviour while maintaining sufficient gene silencing activity [6]. 
Targeted delivery of siRNA to the desired cells and tissues has been considered a big 
challenge in the development of therapeutic siRNA. Specific interaction between a 
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specific ligand and its cellular membrane receptor generally enhances the cellular 
uptake by the aid of a mechanism of receptor –mediated endocytosis [7]. 
Small molecules considered as groove binders or intercalators have also received 
considerable interest as potential groups for conjugation to oligonucleotides [8]. These 
conjugates do not primarily exhibit enhanced cellular uptake or cell-type specific 
targeting, but they can stabilize nucleic acids structures by π-stacking interactions as 
they are usually planar aromatic molecules. Conjugation at any terminus of 
oligoribonucleotides could also prevent degradation by exonucleases. In addition, these 
molecules are constituted of chromophores that could be used to study intracellular 
distribution of nucleic acids. 
Different strategies are used to introduce these derivatives to the 
oligonucleotides. One strategy is based on the introduction of the ligands during solid 
phase synthesis of the oligonucleotides either as a phosphoramidite derivative or as a 
modified nucleoside or solid support [9]. The second strategy consists of the 
conjugation of the derivative and the oligonucleotide using a post synthetic approach 
[10]. 
Several derivatives including acridine, porphyrin, quindoline and other 
polycyclic molecules have been reported to bind and stabilize different nucleic acids 
structures. In particular, oligonucleotide conjugates carrying these compounds have 
been used in the antisense field showing improved uptake, and biodistribution as well as 
increased triplex stability [11]. 
Small interfering RNA (siRNA) is formed of two complementary strands (guide 
and passenger) so there are four terminal ends for potential conjugation sites. Previous 
studies have demonstrated that 3’ and 5’ ends of the sense strand and the 3’ end of the 
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antisense are considered the best sites for conjugation without decreasing RNAi activity 
[12]. 
In this paper we have synthesized and evaluated several oligonucleotide 
conjugates containing single or multiple acridine or quindoline derivatives for siRNA 
studies (Scheme 1). Previously, we have used monomers of these intercalating agents to 
prepare oligodeoxynucleotide conjugates using solid phase methods [13, 14]. Moreover 
acridine has been successfully used to increase delivery of peptide nucleic acids [15]. 
But, to our knowledge, there is no information on the effect of acridines in RNA 
interference. In this article, siRNA containing acridine and quindoline moieties were 
tested for the inhibition of tumour necrosis factor (TNF-a) protein which is involved in 
apoptosis, inflammation and immunity processes [16]. Acridine or quindoline moieties 
may favour stability of the siRNA or prevent nuclease degradation, thus improving 
pharmacokinetic properties of these conjugates. 
  
Scheme 1 
 
Results and Discussion. 1. Synthesis of Oligonucleotides. Conjugation of 
oligonucleotides to intercalating compounds has been demonstrated by direct in-line 
incorporation or by post-synthetic methods [9, 10]. The direct incorporation of the 
intercalating drug requires the preparation of the appropriate derivative compatible with 
the phosphoramidite method. In addition the resulting conjugate should be stable to 
deprotection conditions. In the first studies we used a solid support functionalized with 
a derivative of acridine that was commercially available. Unfortunately, the resulting 
conjugate did not survive the ammonia and fluoride treatments. For that we selected the 
threoninol derivatives of acridine and quindoline (Scheme 1) which have been described 
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to be stable to ammonia [13, 14, 17].  L-threoninol was used as starting material for the 
preparation of the corresponding phosphoramidite monomers and solid supports 
containing the intercalating units. Threoninol has been previously described for the 
introduction of dyes, photoactive azabenzenes and DNA-binding drugs in 
oligonucleotides [14, 18, 19]. Recently, siRNA derivatives carrying aromatic groups 
linked through threoninol at their 3’-end were prepared to modulate binding of a 
passenger strand to the RISC complex [17]. The synthesis of the threoninol derivatives 
of acridine and quindoline (Scheme 2) has been previously described [13]. 
 
Scheme 2 
 
Modified oligoribonucleotide sequences of the TNF-a gene carrying acridine 
and quindoline at the 5’-end or at the 3’-end (1-6, Table 1) were synthesized using the 
appropriate phosphoramidites and solid supports of acridine and quindoline (Scheme 2). 
These RNA sequences are the passenger and the guide strands of a siRNA described to 
downregulate TNF-a [16]. Oligoribonucleotides 1-6 presented a major peak along with 
some impurities (Fig. 1) that were easily separated by HPLC obtaining the desired 
conjugates in good yields.  
 
Figure 1 
 
The good results obtained in these syntheses proved the stability of the acridine-
and quindoline-threoninol derivatives in both ammonia and fluoride deprotection 
conditions. For these reasons, sequences 7-8 having four acridine or quindoline units 
were synthesized using the commercially available symmetric doubler (DB). This 
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phosphoramidite was added two consecutive times at the 5’-termini generating four 
sites for the attachment of acridine or quindoline phosphoramidites. In this way, 5’- 
modified RNA conjugates with four intercalating units were obtained. Yields were 
moderated as the coupling of the branching units was less efficient than standard 
phosphoramidites [20]. RNA strands with intercalating units at the end of the sequences 
were easily purified by HPLC from the truncated sequences as these products are less 
retained in the chromatographic column. Figure 2 shows the HPLC profile of 
oligonucleotide sequence 8 carrying four quindoline units. The desired RNA strand had 
a retention time of 16.7 min. Mass spectrometry analysis confirmed the expected 
molecular weight (Table 1). This indicates that the acridine- and quindoline-conjugates 
are stable to oligonucleotide synthesis conditions. 
 
Figure 2 
 
2. Thermal denaturation studies. Thermal denaturation studies are summarized 
in Table 1. The presence of the acridine and quindoline moiety induced a small 
stabilization of the duplex structure. In general, duplexes containing quindoline have a 
higher melting temperature than acridine conjugates (except siRNA 1 and 2). This 
increased stabilization of quindoline derivatives compared to acridine derivatives have 
also been found in quadruplex structures [13]. Melting temperatures of duplexes 
containing 3’ modifications are similar to those of 5’-modified duplexes. 
Oligonucleotide duplexes carrying four acridine or quindoline molecules 7 and 8 have 
lower melting temperatures than the unmodified duplex. Nevertheless, the small 
destabilization (0.4-0.6 ºC) is in the range of the uncertainty of the melting temperatures 
(0.5 ºC). In summary, the presence of acridine and quindoline modifications in the 
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siRNA duplexes induces a weak stabilization of the siRNA duplex, except in the case of 
tetrasubstituted siRNA. 
 
Table 1 
 
3. Inhibition of tumor necrosis factor. Tumor necrosis factor (TNF-a) was 
selected as a target for RNA interference studies. This protein is a major mediator of 
apoptosis as well as inflammation and immunity, and it has been implicated in the 
pathogenesis of a wide spectrum of human diseases. Consequently inhibition of this 
protein is of particular relevance. Modified oligoribonucleotides where annealed with 
equimolar amounts of the unmodified guide or passenger strands and the resulting 
duplexes were used in the inhibition of the expression of the TNF-a gene. HeLa cells 
were transfected first with the murine TNF-a plasmid using lipofectin and one hour 
later were contransfected with the siRNA duplex (50 nM) using oligofectamine. After 
24 hrs the amount of TNF-a produced by the cells was analyzed by enzyme-linked 
immunoabsorbent assay (ELISA).   
Figure 3  shows the amount of TNF-a produced after 24 hrs of transfection of 
50nM siRNA unmodified duplex (Unm), 50 nM of the same siRNA duplex carrying 
acridine or quindoline derivatives at the 3’-end and 50 nM of a scrambled RNA duplex 
control sequence (Scr). A siRNA carrying cholesterol at the 3’-end of the passenger 
strand (Cho) was also included for comparison purposes. In figure  3A, siRNA modified 
with acridine or quindoline at the 3’ end of the passenger strand produced an inhibition 
of the production of TNF-a around 90% compared to the Scr RNA duplex control and 
slightly better than unmodified siRNA. The inhibition potency is similar to the siRNA 
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carrying cholesterol at the 3’-end of the passenger strand. By contrast, the situation 
changes with siRNAs containing acridine or quindoline in the 3’ end of the guide strand 
(Figure 3B). In this case, a small decrease in the inhibitory activity is found compared to 
unmodified siRNAs although the inhibitory activity is still good compared to Src (80-
85%). This result is in agreement with previous observations on other aromatic 
derivatives at the 3’-end of the guide strand in the inhibition of a luciferase gene [17]. In 
general it can be concluded that the introduction of acridine or quindoline at the 3’-end 
of the passenger or guide strand of an RNA duplex is well tolerated by the RNAi 
machinery and these derivatives do not interfere in the recognition of siRNA by RISC 
complex. 
Figure 3 
In addition we have analyzed the inhibition of the TNF-a production by the 
siRNA duplexes carrying acridine or quindoline in the sense or antisense strand without 
using oligofectamine in HeLa cells (data not shown). In this case there is no inhibition 
of the TNF-a indicating that intercalating modified siRNA duplexes are unable to enter 
HeLa cells. 
Figure 4 shows the amount of TNF-a produced when siRNA unmodified duplex 
(Unmodified), siRNA duplex carrying acridine or quindoline in the 5’-end of sense 
strand and a scrambled RNA duplex control sequence (Scr) were transfected with 
oligofectamine. Moreover, siRNA modified in the sense strand with four acridines or 
quindolines in the 5’-end is also included in this work. Inhibition of TNF-a is around 
75% in the latter case. These results indicate that conjugates of intercalating agents at 
the 5’-end of the sense strand are less effective than unmodified siRNA but they do not 
interfere in the recognition of the RISC complex. Unfortunately, conjugation of these 
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compounds does not enhance cell delivery because the inhibition of TNF-a without 
using oligofectamine in HeLa cells turned out to be similar to unmodified siRNA (data 
not shown). In addition, a small loss of inhibition is detected in siRNA containing 
intercalating agents at the 5’–end of the sense strand compared to the 3’-end of the 
sense strand. In summary, acridine and quindoline derivatives are well tolerated in both 
ends of the sense strand and in the 3’-end of the antisense strand. The addition of four 
acridine or quindoline derivatives in the 5’-end of the sense strand do not enhance 
inhibitory activity compared with a single modification.  
Figure 4 
 
4. Cellular uptake. When HeLa cells were incubated with acridine and 
quindoline siRNA duplexes, the cells became highly fluorescent especially cells treated 
with acridine siRNA duplexes. In order to distinguish between the fluorescence due to 
membrane absorption or the fluorescence due to cellular uptake, confocal microscopy 
studies were performed.  Fluorescence was only observed when acridine siRNA was 
transfected with lipofectamine. As seen in Figure 5A, transfection of acridine-modified 
siRNA is highly efficient and the fluorescence is localized in the cytoplasm where the 
siRNA mechanism is active indicating that the fluorescent properties of acridine can be 
used for the direct observation of cellular uptake of siRNA. 
Figure 5 
Conclusions. We have reported an efficient strategy for the introduction of one 
or several acridine and quindoline molecules at the 3’- or 5’-position of RNA molecules 
that are stable to oligonucleotide synthesis conditions.  We have analyzed the effect of 
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3’-or 5’- insertions on the inhibitory properties of TNF-a in HeLa cells. Modified 
siRNAs containing intercalating compounds are as efficient as unmodified siRNA using 
oligofectamine. Multiple intercalating agents have been introduced in the 5’-end of the 
sense strand. This large structure does not interfere in the RNAi pathway to silence gene 
expression but has similar efficiency compared to single modifications. No inhibition of 
siRNA conjugates was observed when cells where transfected without oligofectamine. 
The fluorescent properties of acridine were used to study cell delivery. Transfection of 
siRNAs modified with acridine showed a clear cytoplasmatic localization of siRNAs in 
HeLa cells. 
 
This study was supported by the Spanish Ministry of Education (CTQ2010-
20541), Generalitat de Catalunya (2009/SGR/208). CIBER-BBN is an initiative funded 
by the VI National R&D&i Plan 2008-2011, Iniciativa Ingenio 2010, Consolider 
Program, CIBER Actions and financed by the Instituto de Salud Carlos III with 
assistance from the European Regional Development Fund.  
 
Experimental Part 
 
Mass spectrometry (MALDI-TOF) was recorded on a Fisons VG Tofspec 
spectrometer and ESI mass spectra on a Fisons VG Plattform II spectrometer. 
Oligonucleotide sequences were prepared using solid phase methodology. The 
syntheses were carried out on an Applied Biosystems Model 3400 DNA synthesizer 
using 1 μmol scale. Oligoribonucleotides were purified by DMT on- based protocols 
and by reversed-phase HPLC. 
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Oligonucleotides. The following RNA sequences were obtained from commercial 
sources (Sigma-Proligo, Dharmacon): sense or passenger scrambled 5’-CAG UCG 
CGU UUG CGA CUG GTT-3’, antisense or guide scrambled 5’-CCA GUC GCA AAC 
GCG ACU GTT-3’, antisense or guide anti-TNFa: 5’-GAG GCU GAG ACA UAG 
GCA CTT-3’ and sense or passenger anti-TNFa: 5’-GUG CCU AUG UCU CAG CCU 
CTT-3’. RNA monomers in capital letters, T represents thymidine. The 3’-cholesterol 
passenger anti-TNFa: strand 5’- GUG CCU AUG UCU CAG CCU CTT-3’-cholesterol 
was prepared using the cholesterol-tetraethyleneglycol 3’-Cholesteryl-TEG-CPG 
support from commercial sources (Glen Research).  
 
Synthesis of oligoribonucleotide conjugates carrying acridine or quindoline. 
Oligoribonucleotide carrying acridine (Act) or quindoline (Qut) either at the 3’- or the 
5’-end were synthesized by a DNA/RNA synthesizer (Applied Biosystems 3400) using 
2-cyanoethyl phosphoramidites. Sequences with modifications at the 3’-end were 
synthesized with controlled pore glass (CPG) solid supports (0.2 mmol) functionalized 
with the threoninol derivatives of acridine or quindoline (Scheme 2) prepared as 
previously described [13, 14]. Sequences carrying one acridine or one quindoline were 
synthesized on polystyrene solid supports (LV200) using the acridine (Act) or 
quindoline (Qut) phosphoramidites (Scheme 2)  prepared as previously described [13].   
Sequences carrying four acridine or quindoline units were prepared assembling two 
units of the symmetric doubler (DB) phosphoramidite (Glen Research) between the 
RNA sequence and the acridine or quindoline units. The sequences synthesized are 
shown in Table 1.  
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Guanosine was protected with the dimethylaminomethylidene group, cytidine was 
protected with the acetyl group and adenosine with the benzoyl group. The 2’-OH 
protecting group for the RNA monomers was the t-butyldimethylsilyl (TBDMS) group. 
The phosphoramidites were dissolved in dry acetonitrile (0.1M) and a modified cycle 
was used with an increased coupling time of 10 min. The solid supports were treated 
with concentrated aqueous ammonia-ethanol (3:1) for 1hr at 55oC. The supports were 
filtered and washed with ethanol and the combined solutions were evaporated to 
dryness.  Sequences were treated with 0.15 ml of triethylamine.tris(hydrofluoride) / 
triethylamine / N-methylpyrrolidone (4:3:6) for 2.5 hours at 65 ºC to remove the t-
butyldimethylsilyl groups. The reactions were stopped by addition of 0.3 ml of 
isopropoxytrimethylsilane and 0.75 ml of ether. The resulting mixtures were mixed with 
the vortex and cooled at 4 ºC. A precipitate was formed that was centrifuged at 7000 
rpm, 5 min at 4ºC. The precipitates were washed with ether and centrifuged again. The 
residues were dissolved in water and the conjugates were purified by HPLC. HPLC 
conditions were:  column: Nucleosil 120-10 C18 (250x4 mm); 20 min linear gradient 
from 0%  to 50% B (DMT off conditions); flow rate 3 ml/min; solution A was 5% 
acetonitrile in 0.1 M aqueous triethylammonium acetate (TEAA) buffer and B 70% 
acetonitrile in 0.1 M aqueous TEAA. The purified products were analyzed by MALDI-
TOF mass spectrometry (Table 1). Yields (0.2 mmol scale synthesis) were between 10-
15 OD units at 260 nm except for sequences 7 and 8 that were around 5 OD units. 
 
Thermal denaturation studies. The thermal denaturation curves were performed 
monitoring the absorption change at 260 nm for duplexes formed by oligonucleotides 1-
8 and their unmodified complementary strands. Samples were heated from a 
temperature of 20°C to 90°C, with a linear temperature ramp of 0.5°/min in a JASCO 
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V-650 spectrophotometer equipped with a Peltier temperature control. Concentration of 
the samples were around 2mM. All the measurements were repeated three times, 
conducted in 15 mM HEPES 1 mM Mg(OAc)2 mM  50 mM KOAc  pH 7.4 
 
Cell culture, transfection and cellular assays. HeLa cells were cultured under 
standard conditions (37ºC, 5% CO2, Dulbecco’s Modified Eagle Medium, 10% fetal 
bovine serum, 2mM L-glutamine, supplemented with penicillin (100 U/ml) and 
streptomycin (100mg/ml)).  All in vitro experiments were conducted at 40-60% 
confluence. HeLa cells were transfected with 250 ng of murine expressing TNF-a 
plasmid using lipofectin (Invitrogen) according to the manufacturer’s instructions. One 
hour following transfection murine-TNF-a expressing HeLa cells were transfected with 
50nM of siRNA (5’-GUG CCU AUG UCU CAG CCU CTT-3’ / 5’ GAG GCU GAG 
ACA UAG GCA CTT-3’) against TNF-a, using oligofectamine (Invitrogen). TNF-a 
concentration was determined from cell culture supernatant by enzyme-linked 
immunoabsorbent assay kit (Bender MedSystems) according to the manufacturer’s 
instructions.  
 
Cellular uptake studies. For analysis of cellular uptake and distribution, HeLa cells 
were cultured  in 24-well plates with glass cover slip bottoms. siRNA carrying acridine 
was transfected  into HeLa cells using oligofectamine (Invitrogen) according to the 
manufacture’s instructions. The nucleus was stained by Topro-3 (red) 24-h after 
transfection. A series of images were obtained by using a confocal laser scanning 
microscope (BioRad). Acridine fluorescence was detected by exciting at 300 nm and 
emission spectrum was recorded from 350 to 560 nm. The spectrum peak at 358 nm 
represented the fluorescence intensity of acridine and was an indicator of siRNA uptake. 
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LEGENDS 
 
Scheme 1. Structure of oligoribonucleotides carrying acridine and quindoline residues. 
RNA sequences correspond to guide or passenger anti-TNF-a sequences (Table 1). 
 
Scheme 2. Structure of the phosphoramidites and solid supports used in this study for 
the preparation of oligoribonucleotides carrying acridine and quindoline residues. 
 
Fig. 1. Reverse HPLC profiles of 5’- and 3’-modified oligoribonucleotides. A) Acridine-
5’-guide (passenger) strand, 5. B) Quindoline-3’-guide (passenger) strand, 2. 
 
Fig. 2. Reversed phase HPLC profiles of oligonucleotide conjugate 8 carrying four 
quindoline units. 
 
Fig. 3.  Plot of gene-specific silencing activities for 3’-acridine and 3’-quindoline 
oligonucleotide conjugates with transfecting agent at 50 nM. A) Modifications at the 3’-
end of the passenger strand. B) Modifications at the 3’-end of the guide strand. Unm: 
unmodified siRNA duplex, Scr: scrambled siRNA duplex, Cho: siRNA carrying a 
cholesterol molecule at the 3’-end of the passenger strand.  
 
Fig. 4. Plot of gene-specific silencing activities of 5’-acridine and 5’-quindoline 
oligonucleotide conjugates with transfecting agent at 50 nM. In all cases modifications 
at the 5’-end were in the passenger strand. 
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Fig. 5.  Cellular uptake of siRNA conjugate carrying acridine. A) HeLa cells were 
transfected with siRNA carrying acridine (1) using lipofectamine. B) HeLa cells were 
transfected with siRNA (1) without using lipofectamine. After 24 hr, HeLa cells were 
fixed in 10% paraformaldehyde at room temperature for 10 min and then subjected to 
TOPRO-3 staining. Localization of the duplex siRNA was monitored by Leica confocal 
microscopy. Overlay image of siRNA (blue) and nucleus (red) (TOPRO-3) is shown 
here.  
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Table 1. Oligoribonucleotide Sequences Used for the Preparation of the Corresponding 
siRNA Conjugates for RNA Interference studies. 
 
# Sequence (5’-3’)a) MSb) Tmc) (DTm) d) 
1 GUGCCUAUGUCUCAGCCUCTT 6931/6926 85.0 (1.7) 
2 GUGCCUAUGUCUCAGCCUCTT-Qut 6970/6968 85.0 (1.7)  
3 GAGGCUGAGACAUAGGCACTT-Act 7144/7146 83.5 (0.2) 
4 GAGGCUGAGACAUAGGCACTT-Qut 7183/7184 84.8 (1.5) 
5 Act-GUGCCUAUGUCUCAGCCUCTT 6931/6929 83.7 (0.4) 
6 Qut-GUGCCUAUGUCUCAGCCUCTT 6970/6968 84.9 (1.6) 
7 (Act)4-DB-DB-GUGCCUAUGUCUCAGCCUCTT 9105/9101 82.7 (-0.6) 
8 (Qut)4-DB-DB-GUGCCUAUGUCUCAGCCUCTT 9261/9251 82.9 (-0.4) 
 
a) Act: acridine threoninol, Qut: Quindoline threoninol, DB: doubler; b) Mass spectra 
(expected/found); c) uncertainty ± 0.5°C; condition: 15 mM HEPES 1 mM Mg(OAc)2 
mM  50 mM KOAc  pH 7.4. Melting temperature of unmodified siRNA is 83.3 ºC; d) 
DTm is the diference between the melting temperature of the modified siRNA minus the 
melting temperature of the corresponding unmodified siRNA. 
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Scheme 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HO O
P O
O-
O RNA
O
O
NH
NH
O
O
O
P
O-O
O
O
O
NH
NH
O
O
O
P
O
-O O
NH
NH
O
O
O
P
O-O
O
RNA
RNA seq
NHCOR
HO O
P
O-
NHCOR
HO O
P
O-
NHCOR
HO O
P
O-
NHCOR
O
O
O
HO O
P
O-
NHCOR
O
7, R= Act
8, R= Qut
5, R= Act
6, R= Qut
O
P O
O-
O OH
1, 3, R= Act
2, 4, R= Qut
NHCOR
N
R= Act
N
R= Qut
N
H
 20
 
 
Scheme 2. 
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Figure 3 
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Figure 5 
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